Fate Therapeutics, Inc. Logo

Press Releases

 
Press Releases
  Date Title and Summary View
Jul 26, 2016
Key Patent Covers Renewable Pluripotent Cell Source for Development of Off-the-Shelf NK- and T-Cell Immunotherapies SAN DIEGO, July 26, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapie...
Jun 20, 2016
SAN DIEGO, June 20, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ProTmune͐...
Jun 16, 2016
SAN DIEGO, June 16, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that it will host a Focus Session entitled "Fighting Cancer with Off-the-Shelf iPSC Immunother...
Jun 11, 2016
One-time Administration of Programmed Cells Demonstrates Durable Disease Correction in Type 1 Diabetes Mouse Model ToleraCyte™ Product Candidate Exhibits Enhanced Trafficking to the Pancreas and Potent Regulation of Autoreactive T Cells in Preclinical Testing...
May 17, 2016
SAN DIEGO, May 17, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Chris M. Storgard, M.D. has joined the Company as its Chief Medical Officer.  Dr. Storgard i...
May 16, 2016
Adaptive NK Cell Therapy Advancing Toward First-in-Human Clinical Trial in Collaboration with University of Minnesota Program to be Presented Today at Innate Killer Summit 2016 SAN DIEGO, May 16, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical...
May 9, 2016
Phase 1/2 Clinical Trial of ProTmune™ for Prevention of Acute GvHD and CMV Infection to Begin Enrollment in mid-2016 Adaptive NK Cell Cancer Immunotherapy to be Featured at Innate Killer Summit in mid-May ...
May 2, 2016
SAN DIEGO, May 02, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast on Monday, May 9, 2016 at 5:00 p.m...
Apr 5, 2016
SAN DIEGO, April 05, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Officer, will be presenting a company overvie...
Mar 3, 2016
ProTmune™ Investigational New Drug Application for Prevention of Acute GvHD and CMV Infection Cleared by FDA in January 2016 Phase 1/2 Clinical Trial of ProTmune to Commence Enrollment in mid-2016 Data Updates for All Preclinical Adoptive Immunothera...
Page: FirstPrevious
3
... NextLast
= add release to Briefcase
MENU